-
Boston Scientific Gains Momentum As Growth Broadens, Goldman Sachs Says
Wednesday, October 22, 2025 - 12:21pm | 406Read More...Boston Scientific Corp (NYSE:BSX) delivered "another set of strong top-line results," which trickled down to an earnings beat, according to Goldman Sachs. BSX stock is showing exceptional strength. Check the market position here. The Boston Scientific Analyst: Analyst David Roman reiterated a Buy...
-
Intuitive Surgical Posts Q3 Earnings Beat, These Analysts Raise Forecasts On DV5 Uptake
Friday, October 18, 2024 - 12:19pm | 768Read More...Intuitive Surgical, Inc. (NASDAQ:ISRG) Thursday reported upbeat earnings for its third quarter. The company reported its results amid an exciting earnings season. Here are some key analyst takeaways. RBC Capital Markets analyst Shagun Singh reiterated an Outperform rating, while raising the price...
-
LivaNova's New Strategy Could Unlock Revenue, Profit Gains, Analyst Predicts
Friday, October 4, 2024 - 11:59am | 335Read More...Shares of LivaNova Plc (NASDAQ:LIVN) Tuesday climbed along with several other big stocks. There is high visibility into the company's near-term baseline growth, with potential upside to revenue and earnings from "new product cycles and pipeline optionality," according to Goldman Sachs. Analyst...
-
Goldman Takes Haemonetics Off Sell List, Upgrades To Neutral
Monday, May 16, 2016 - 11:27am | 214Read More...Goldman Sachs has upgraded Haemonetics Corporation (NYSE: HAE) to Neutral and removed the stock from "Americas Sell List," saying that "consensus numbers and management expectations appear rebased with risk/reward in the stock more balanced." The healthcare company recently issued its fiscal 2017...
-
Goldman Sachs' New Pair Trade? Bull Zeltiq Aesthetics, Bear NuVasive
Wednesday, June 3, 2015 - 3:27pm | 397Read More...In a report published Tuesday, Goldman Sachs analyst David Roman revisited the small-cap names under his coverage and noted that he is sticking with his view that product cycles and U.S. cyclical exposure (hospital capex/utilization) remain the "most prominent" drivers of upside....
-
UPDATE: Goldman Sachs Initiates Haemonetics at Neutral on Stable Outlook
Friday, May 31, 2013 - 9:25am | 134Read More...In a report published on Friday, Goldman Sachs analyst David Roman initiated coverage on Haemonetics (NYSE: HAE) with a Neutral rating and a price target of $47.00. In the report, Goldman Sachs stated, "The fundamental outlook for Haemonetics appears relatively stable with the vast majority of...
